imatinib mesylate has been researched along with Carcinoma, Medullary in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, MS; Hussain, HB; Moley, JF | 1 |
| de Groot, JW; Eggen, BJ; Hofstra, R; Links, T; Plaza Menacho, I; Plukker, J | 1 |
| Nevins, JR; Wells, SA | 1 |
| Kim, LT; Nwariaku, F; Panta, GR | 1 |
| Asa, SL; Dackiw, A; Ezzat, S; Huang, P | 1 |
| Bergan, RC; Campbell, SC; He, X; Huang, X; Perlman, EJ; Pins, M; Simpson, L; Yang, XJ | 1 |
| de Groot, JW; Links, TP; Plukker, JT; van Der Graaf, WT; Zonnenberg, BA | 1 |
| de Groot, JW; Drenth-Diephuis, LJ; Eggen, BJ; Hofstra, RM; Links, TP; Osinga, J; Plaza Menacho, I; Plukker, JT; Schepers, H | 1 |
| de Groot, JW; de Vries, MM; Links, TP; Lips, CJ; van Ufford-Mannesse, PQ; Voest, EE; Zonnenberg, BA | 1 |
| Delorme, S; Fabel, M; Frank-Raue, K; Haberkorn, U; Raue, F | 1 |
3 trial(s) available for imatinib mesylate and Carcinoma, Medullary
| Article | Year |
|---|---|
Imatinib induces hypothyroidism in patients receiving levothyroxine.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Medullary; Drug Synergism; Female; Gastrointestinal Stromal Tumors; Humans; Hypothyroidism; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Thyroid Neoplasms; Thyroidectomy; Thyrotropin; Thyroxine; Triiodothyronine | 2005 |
A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Medullary; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Thyroid Neoplasms; Treatment Outcome | 2007 |
Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Calcitonin; Carcinoma, Medullary; Female; Fluorodeoxyglucose F18; Germ-Line Mutation; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Proto-Oncogene Mas; Pyrimidines; Survival Analysis; Thyroid Neoplasms | 2007 |
7 other study(ies) available for imatinib mesylate and Carcinoma, Medullary
| Article | Year |
|---|---|
Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors.
Topics: Benzamides; Benzoquinones; Carcinoma, Medullary; Cell Division; Drosophila Proteins; Enzyme Inhibitors; Genistein; Humans; Imatinib Mesylate; Lactams, Macrocyclic; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Pyrimidines; Quinones; Receptor Protein-Tyrosine Kinases; Thyroid Neoplasms; Tumor Cells, Cultured | 2002 |
Re: "Inhibition of medullary thyroid carcinoma (MTC) cell proliferation and RET phosphorylation by tyrosine kinase inhibitors".
Topics: Benzamides; Carcinoma, Medullary; Cell Division; Enzyme Inhibitors; Humans; Imatinib Mesylate; Oncogene Proteins; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-ret; Pyrimidines; Receptor Protein-Tyrosine Kinases; Thyroid Neoplasms | 2004 |
Evolving strategies for targeted cancer therapy--past, present, and future.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Medullary; DNA, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Multiple Endocrine Neoplasia Type 2a; Multiple Endocrine Neoplasia Type 2b; Oligonucleotide Array Sequence Analysis; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Pyrimidines; Receptor Protein-Tyrosine Kinases; Thyroid Neoplasms; Thyroidectomy | 2004 |
RET signals through focal adhesion kinase in medullary thyroid cancer cells.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Medullary; Cell Line, Tumor; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Humans; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Proto-Oncogenes; Pyrimidines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Thyroid Neoplasms | 2004 |
Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth.
Topics: Animals; Apoptosis; Benzamides; Carcinoma, Medullary; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; Imatinib Mesylate; Mice; Oncogene Proteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 4; Receptors, Fibroblast Growth Factor; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2005 |
Renal medullary carcinoma and ABL gene amplification.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Medullary; Cell Survival; Child; Child, Preschool; Combined Modality Therapy; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Genes, abl; Genes, Tumor Suppressor; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Kidney; Kidney Neoplasms; Male; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcr; Pyrimidines; Risk Factors; Sickle Cell Trait; Survival Rate; Treatment Failure | 2005 |
Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.
Topics: Apoptosis; Benzamides; Carcinoma, Medullary; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Multiple Endocrine Neoplasia Type 2a; Multiple Endocrine Neoplasia Type 2b; Mutation; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-ret; Pyrimidines; Thyroid Neoplasms | 2006 |